Document series
Trial abstracts — page 22
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 22 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| GETGOAL-DUO-1-RENAL-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2013 | Very low |
| GETGOAL-L-BODY-COMPprogramme record | Lixisenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| GETGOAL-L-DDIprogramme record | Lixisenatide | Phase 1 | Reported | Randomised crossover | — | 2013 | Very low |
| GETGOAL-L-HEPATIC-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2013 | Very low |
| GETGOAL-L-PKprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2013 | Very low |
| GETGOAL-L-RENAL-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2013 | Very low |
| GETGOAL-M-ADHERENCEprogramme record | Lixisenatide | Phase 3 | Reported | Observational | — | 2013 | Very low |
| GETGOAL-M-BIOMARKERprogramme record | Lixisenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| GETGOAL-M-ELDERLYprogramme record | Lixisenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| GETGOAL-M-OLEprogramme record | Lixisenatide | Phase 3 | Reported | Single-arm open-label | — | 2013 | Very low |
| GETGOAL-M-RENAL-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2013 | Very low |
| STEPS-2-ADHERENCEprogramme record | Teduglutide | Phase 3 | Reported | Observational | — | 2013 | Very low |
| STEPS-2-BIOMARKERprogramme record | Teduglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| STEPS-2-ELDERLYprogramme record | Teduglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| STEPS-2-OLEprogramme record | Teduglutide | Phase 3 | Reported | Single-arm open-label | — | 2013 | Very low |
| TA1-SEPSIS-CN-ADHERENCEprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Observational | — | 2013 | Very low |
| TA1-SEPSIS-CN-BIOMARKERprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| TA1-SEPSIS-CN-ELDERLYprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| TA1-SEPSIS-CN-OLEprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Single-arm open-label | — | 2013 | Very low |
| TB4-PH2-VENOUSULCER-ADHERENCEprogramme record | Thymosin beta-4 | Phase 2 | Reported | Observational | — | 2013 | Very low |
| TB4-PH2-VENOUSULCER-BIOMARKERprogramme record | Thymosin beta-4 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| TB4-PH2-VENOUSULCER-ELDERLYprogramme record | Thymosin beta-4 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| TB4-PH2-VENOUSULCER-OLEprogramme record | Thymosin beta-4 | Phase 2 | Reported | Single-arm open-label | — | 2013 | Very low |
| STEPS-DDIprogramme record | Teduglutide | Phase 1 | Reported | Randomised crossover | — | 2012 | Very low |
page 22 of 30